AstraZeneca, BMS in talks over $400b mega-merger that would reshape global pharma

British pharmaceutical giant AstraZeneca and US drugmaker Bristol Myers Squibb are pursuing a mega-merger that would value the combined entity at $400 billion (577 trillion won), in what would be the largest deal in pharmaceutical history. If completed, the transaction would create a dominant oncology powerhouse spanning immuno-oncology and antibody-drug conjugate therapies, fundamentally redrawing the global pharmaceutical landscape.

The two companies have held merger discussions over the past several months and are in final-stage negotiations aimed at closing a deal in the near term, the Financial Times reported Monday. AstraZeneca currently carries a market capitalization of about $265 billion, while BMS stands at roughly 192 trillion won. A combined entity would instantly become the world's fourth-largest pharmaceutical company by market capitalization.

Both AstraZeneca and BMS have declined to comment on the merger reports. The Financial Times noted that while a deal could be reached soon, it could also be delayed or fall through entirely.

The most closely watched aspect of the potential merger is by far the synergy between the two companies' oncology portfolios. BMS holds Opdivo, a globally blockbuster immuno-oncology drug, while AstraZeneca has led the global cancer market with Tagrisso for lung cancer, Imfinzi as an immuno-oncology agent, and Enhertu — a next-generation ADC therapy co-developed with Daiichi Sankyo.

The merger amounts to more than a simple expansion in scale — analysts widely read it as a strategic move to seize full control of the next-generation cancer treatment market. Some analysts say it represents a win-win: BMS would use AstraZeneca's next-generation ADC and targeted oncology pipeline to offset the patent-expiry risk threatening its key products, while AstraZeneca would gain an immediate foothold in the US market — its largest — along with an established distribution network, advancing its goal of reaching $80 billion in annual sales by 2030.

The drive among global pharmaceutical majors to pursue large-scale M&A is rooted in the looming revenue cliff created by patent expirations on their most profitable drugs. BMS, facing the upcoming patent expiry of Opdivo and other key products, was under mounting pressure to secure new growth engines. The attempted merger clearly illustrates a survival strategy now common across the industry: as internal R&D alone hits its limits, companies are aggressively absorbing target technologies and market share through acquisitions.

The mega-merger is expected to send significant ripples through South Korea's pharmaceutical and biotech sector as well. The creation of such a combined giant would dramatically accelerate the scale and pace of global clinical trials, raising barriers to market entry for smaller, later-moving players.

At the same time, some observers note that the merger process — which would require the combined company to rationalize overlapping pipelines and evaluate new next-generation technologies — could actually expand licensing-out opportunities for Korean biotech firms with competitive platform technologies and pipelines.

However, the path to a final deal remains steep. The biggest obstacle is antitrust review by global regulators. Both companies hold dominant positions in the oncology market, so authorities are expected to scrutinize the deal closely over concerns about price increases and reduced competition stemming from such a concentration of market power.

Strong pushback from British politicians and the financial community over the possibility of AstraZeneca shifting its center of gravity to the United States — or even relocating its headquarters — adds another layer of uncertainty. With CEO Pascal Soriot aggressively pushing US market expansion, the prospect of one of Britain's most prized pharmaceutical companies being absorbed into the American sphere is likely to escalate into a political controversy.